A link between obesity and type 2 diabetes has been noted for millennia, and particularly in more recent centuries, with the global obesity epidemic drawing it to modern attention. The evidence associating obesity with deteriorating glycaemic control, the development of type 2 diabetes and negative influence on its pathogenesis is increasing, as is the focus on the co-existence of the conditions – namely ‘diabesity’. The pharmacological therapies for type 2 diabetes which are weight neutral or facilitate weight loss are metformin, the more recently introduced agents which target the incretin system and dapagliflozin, the sodium-glucose transporter 2 (SGLT2) inhibitor. These therapies are appropriate for the treatment of diabesity since they reduce hyperglycaemia and concomitantly address the underlying pathology of weight control.
JoslinElliott P.A Diabetic Manual for the Mutual Use of Doctor and Patient. 7th ed.Philadelphia: Lea & Febiger, 1941.
2.
CarnethonMRDe ChavezPJDBiggsML. Association of weight status with mortality in adults with incident diabetes. JAMA2012; 308: 581-90.
3.
StevensJCouperDPankowJ. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res2001; 9: 696-705.
4.
HillierTAPedulaKL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care2001; 24: 1522-7.
SchafferJE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol2003; 14: 281-7.
7.
BalistreriCRCarusoCCandoreG. The role of adipose tissue and adipokines in obesity-related inflammatory diseases mediators. Mediators Inflamm2010; 2010: 802078.
8.
KojimaSFunahashiTMaruyoshiH. Levels of the adipocyte derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res2005; 115: 483-90.
9.
WozniakSGeeLLWachtelMSFrezzaEE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci2009; 54: 1847-56.
10.
KaufmanFR. Diabesity: a doctor and her patients on the front lines of the obesity-diabetes epidemic. New York: Bantam Books, 2006.
11.
SimsEAHDanforthEHortonES. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Hormone Res1973; 29: 457-96.
12.
RolloJ. An account of two cases of the diabetes mellitus with remarks as they arose during the progress of the cure. London: Pub Dilly, 1797.
13.
BouchardatA. De la glycosurie ou la diabete sucre. Paris, 1873.
14.
LancereauxE. Le diabete maigre; ses symptoms son evolution son prognostic et son traitement: ses rapports avec les alterations du pancreas. Union Med1880; 29: 161-8.
15.
JoslinEP. Symposium on diabetes: changes in the diabetic clientele. JAMA1924; 82.
16.
JoslinEP. The diabetic problem of today. JAMA1924; 83: 10JAMA. 1924; 83: 727-729
17.
BowcockHM. Diabetes mellitus in the negro race: A study of one hundred consecutive cases. Southern Medical Journal1928; 21: 994–998.
HimsworthHP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet1936; 227: 127-30.
20.
DançelF. Obesity or Excessive Corpulence: The Various Causes and the Rational Means of Cure. 3rd edn. Toronto: Pub Chewett & Co, 1864.
21.
ErikssonKF LF. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia1998; 41: 1010-16.
22.
PanXRLiGWHuYH. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care1997; 20: 537-44.
23.
LindströmJLouherantaAMannelinM. For the Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS) Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care2003; 26: 3230-6.
24.
RamachandranASnehalathaCMaryS. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia2006; 49: 289-97.
25.
KnowlerWCBarrett-ConnorEFowlerSE. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393-403.
26.
HolmanRRPaulSKBethelMA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008; 359: 1577-89.
27.
Diabetes UK. Warning about the one in 70 people who have undiagnosed Type 2 diabetes. 11June2012. (Accessed 8 December 2012).
28.
GriffinSJBorch-JohnsenKDaviesMJ. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet2011; 378: 156-67.
29.
WoolthuisEPKde GrauwWJCvan GerwenWHEM. Yield of opportunistic targeted screening for type 2 diabetes in primary care: the diabscreen study. Ann Fam Med2009; 7: 422-30.
30.
WingRRMarcusMDEpsteinLHSalataR. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care1987; 10: 563-66.
31.
WaddenTANeibergRHWingRR. The Look AHEAD Research Group. Four-Year Weight Losses in the Look AHEAD Study: Factors Associated with Long-Term Success. Obesity (Silver Spring)2011; 19: 1987-98.
32.
BelalcazarLMBallantyneCMLangW. The Look AHEAD (Action for Health in Diabetes) Research Group. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes. Findings from the Look AHEAD Study. Arterioscler Thromb Vasc Biol2011; 31: 1689-95.
33.
The Look AHEAD Research Group. The Look AHEAD Study. A Description of the Lifestyle Intervention and the Evidence Supporting It. Obesity2006; 14: 737-52.
GaedePVedelPLarsenN. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003; 348: 383-3.
36.
GædePLund-AndersenHParvingH-HPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580-91.
37.
SantosFLEstevesSSda Costa PereiraA. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev2012; 13: 1048-66.
38.
GardnerCDKiazandAAlhassanS. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women. The A TO Z Weight Loss Study: a randomized trial. JAMA2007; 297: 969-77.
39.
ShaiISchwarzfuchsDHenkinY. For the Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet. N Engl J Med2008; 359: 229-41.
40.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008; 358: 2545-59.
41.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837-53.
42.
GoldsteinDJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992; 16: 397-415.
43.
WildingJ. Results of the LEAD2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. Br J Diabetes Vasc Dis2009; 9: 177-85.
44.
KlonoffDCBuseJBNielsenLL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin2008; 24: 275-86.
45.
NauckMSmithU. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?Best Pract Res Clin Endocrinol Metab2009; 23: 513-23.
46.
PratleyRENauckMBaileyT. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet2010; 375: 1447-56.
47.
BolinderJJunggrenOKullbergJ. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab2012; 97: 1020-31.
48.
YipKHeinbergLGiegerichV. Equivalent weight loss with marked metabolic benefit observed in a matched cohort with and without type 2 diabetes 12 months following gastric bypass surgery. Obes Surg2012; 22: 1723-29.
49.
RydénATorgersonJS.The Swedish Obese Subjects Study: what has been accomplished to date?Surg Obes Rel Dis2006; 2: 549-60.
